Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy

G. M. Peterson, K. D. Fitzmaurice, M. Naunton, J. H. Vial, K. Stewart, H. Krum

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Objective: To evaluate a pharmacist-conducted educational and monitoring programme, designed to promote dietary and lifestyle modification and compliance with lipid-lowering drug therapy, for patients with dyslipidaemia. Methods: This was a prospective, randomized, controlled study. The participants were 94 adults, with 81 completing the study (intervention group: 39; control group: 42), with a cardiovascular-related diagnosis and discharged from hospital, between April and October 2001, on lipid-lowering drug therapy. Patients in the intervention group were visited at home monthly by a pharmacist, who educated the patients on the goals of lipid-lowering treatment and the importance of lifestyle issues in dyslipidaemia and compliance with therapy, assessed patients for drug-related problems, and measured total blood cholesterol levels using point-of-care testing. Patients in the control group received standard medical care. The main outcome measure was total blood cholesterol levels after 6 months, and an evaluation of patient and general practitioner satisfaction with the programme. Results: There was no significant difference in baseline total blood cholesterol levels between the two groups. The reduction over the course of the study in cholesterol levels within the intervention group was statistically significant (4-9 ± 0.7 to 4.4 ± 0.6, P < 0.005), whereas there was no change within the control group (P = 0.26). At follow-up, 44% of the intervention group patients and 24% of the control group patients had cholesterol levels below 4.0 mmol/L (P = 0.06). The reduction in total cholesterol in the intervention group should translate to an expected 21% reduction in cardiovascular mortality risk and a 16% reduction in total mortality risk - more than twice the risk reduction achieved in the control group. In addition, the programme was very well received by the patients and their general practitioners, by satisfaction questionnaire. Conclusion: A pharmacist-conducted educational and monitoring intervention improved the outcomes of lipid-lowering drug therapy.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalJournal of Clinical Pharmacy and Therapeutics
Volume29
Issue number1
DOIs
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

House Calls
Pharmacists
Lipids
Drug Therapy
Cholesterol
Control Groups
Dyslipidemias
General Practitioners
Life Style
Diet Therapy
Mortality
Risk Reduction Behavior
Outcome Assessment (Health Care)

Cite this

Peterson, G. M. ; Fitzmaurice, K. D. ; Naunton, M. ; Vial, J. H. ; Stewart, K. ; Krum, H. / Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. In: Journal of Clinical Pharmacy and Therapeutics. 2004 ; Vol. 29, No. 1. pp. 23-30.
@article{38a1b7a9de76452db9c05c30a4dccca6,
title = "Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy",
abstract = "Objective: To evaluate a pharmacist-conducted educational and monitoring programme, designed to promote dietary and lifestyle modification and compliance with lipid-lowering drug therapy, for patients with dyslipidaemia. Methods: This was a prospective, randomized, controlled study. The participants were 94 adults, with 81 completing the study (intervention group: 39; control group: 42), with a cardiovascular-related diagnosis and discharged from hospital, between April and October 2001, on lipid-lowering drug therapy. Patients in the intervention group were visited at home monthly by a pharmacist, who educated the patients on the goals of lipid-lowering treatment and the importance of lifestyle issues in dyslipidaemia and compliance with therapy, assessed patients for drug-related problems, and measured total blood cholesterol levels using point-of-care testing. Patients in the control group received standard medical care. The main outcome measure was total blood cholesterol levels after 6 months, and an evaluation of patient and general practitioner satisfaction with the programme. Results: There was no significant difference in baseline total blood cholesterol levels between the two groups. The reduction over the course of the study in cholesterol levels within the intervention group was statistically significant (4-9 ± 0.7 to 4.4 ± 0.6, P < 0.005), whereas there was no change within the control group (P = 0.26). At follow-up, 44{\%} of the intervention group patients and 24{\%} of the control group patients had cholesterol levels below 4.0 mmol/L (P = 0.06). The reduction in total cholesterol in the intervention group should translate to an expected 21{\%} reduction in cardiovascular mortality risk and a 16{\%} reduction in total mortality risk - more than twice the risk reduction achieved in the control group. In addition, the programme was very well received by the patients and their general practitioners, by satisfaction questionnaire. Conclusion: A pharmacist-conducted educational and monitoring intervention improved the outcomes of lipid-lowering drug therapy.",
keywords = "Cholesterol, Compliance, Education, Lipid-lowering drug therapy, Monitoring, Outcomes",
author = "Peterson, {G. M.} and Fitzmaurice, {K. D.} and M. Naunton and Vial, {J. H.} and K. Stewart and H. Krum",
year = "2004",
doi = "10.1046/j.1365-2710.2003.00532.x",
language = "English",
volume = "29",
pages = "23--30",
journal = "Journal of Clinical and Hospital Pharmacy",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "1",

}

Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. / Peterson, G. M.; Fitzmaurice, K. D.; Naunton, M.; Vial, J. H.; Stewart, K.; Krum, H.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 29, No. 1, 2004, p. 23-30.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy

AU - Peterson, G. M.

AU - Fitzmaurice, K. D.

AU - Naunton, M.

AU - Vial, J. H.

AU - Stewart, K.

AU - Krum, H.

PY - 2004

Y1 - 2004

N2 - Objective: To evaluate a pharmacist-conducted educational and monitoring programme, designed to promote dietary and lifestyle modification and compliance with lipid-lowering drug therapy, for patients with dyslipidaemia. Methods: This was a prospective, randomized, controlled study. The participants were 94 adults, with 81 completing the study (intervention group: 39; control group: 42), with a cardiovascular-related diagnosis and discharged from hospital, between April and October 2001, on lipid-lowering drug therapy. Patients in the intervention group were visited at home monthly by a pharmacist, who educated the patients on the goals of lipid-lowering treatment and the importance of lifestyle issues in dyslipidaemia and compliance with therapy, assessed patients for drug-related problems, and measured total blood cholesterol levels using point-of-care testing. Patients in the control group received standard medical care. The main outcome measure was total blood cholesterol levels after 6 months, and an evaluation of patient and general practitioner satisfaction with the programme. Results: There was no significant difference in baseline total blood cholesterol levels between the two groups. The reduction over the course of the study in cholesterol levels within the intervention group was statistically significant (4-9 ± 0.7 to 4.4 ± 0.6, P < 0.005), whereas there was no change within the control group (P = 0.26). At follow-up, 44% of the intervention group patients and 24% of the control group patients had cholesterol levels below 4.0 mmol/L (P = 0.06). The reduction in total cholesterol in the intervention group should translate to an expected 21% reduction in cardiovascular mortality risk and a 16% reduction in total mortality risk - more than twice the risk reduction achieved in the control group. In addition, the programme was very well received by the patients and their general practitioners, by satisfaction questionnaire. Conclusion: A pharmacist-conducted educational and monitoring intervention improved the outcomes of lipid-lowering drug therapy.

AB - Objective: To evaluate a pharmacist-conducted educational and monitoring programme, designed to promote dietary and lifestyle modification and compliance with lipid-lowering drug therapy, for patients with dyslipidaemia. Methods: This was a prospective, randomized, controlled study. The participants were 94 adults, with 81 completing the study (intervention group: 39; control group: 42), with a cardiovascular-related diagnosis and discharged from hospital, between April and October 2001, on lipid-lowering drug therapy. Patients in the intervention group were visited at home monthly by a pharmacist, who educated the patients on the goals of lipid-lowering treatment and the importance of lifestyle issues in dyslipidaemia and compliance with therapy, assessed patients for drug-related problems, and measured total blood cholesterol levels using point-of-care testing. Patients in the control group received standard medical care. The main outcome measure was total blood cholesterol levels after 6 months, and an evaluation of patient and general practitioner satisfaction with the programme. Results: There was no significant difference in baseline total blood cholesterol levels between the two groups. The reduction over the course of the study in cholesterol levels within the intervention group was statistically significant (4-9 ± 0.7 to 4.4 ± 0.6, P < 0.005), whereas there was no change within the control group (P = 0.26). At follow-up, 44% of the intervention group patients and 24% of the control group patients had cholesterol levels below 4.0 mmol/L (P = 0.06). The reduction in total cholesterol in the intervention group should translate to an expected 21% reduction in cardiovascular mortality risk and a 16% reduction in total mortality risk - more than twice the risk reduction achieved in the control group. In addition, the programme was very well received by the patients and their general practitioners, by satisfaction questionnaire. Conclusion: A pharmacist-conducted educational and monitoring intervention improved the outcomes of lipid-lowering drug therapy.

KW - Cholesterol

KW - Compliance

KW - Education

KW - Lipid-lowering drug therapy

KW - Monitoring

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=1342288936&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2710.2003.00532.x

DO - 10.1046/j.1365-2710.2003.00532.x

M3 - Article

VL - 29

SP - 23

EP - 30

JO - Journal of Clinical and Hospital Pharmacy

JF - Journal of Clinical and Hospital Pharmacy

SN - 0269-4727

IS - 1

ER -